308 related articles for article (PubMed ID: 34030964)
1. Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi Resistance.
Andronikou C; Rottenberg S
Trends Mol Med; 2021 Jul; 27(7):630-642. PubMed ID: 34030964
[TBL] [Abstract][Full Text] [Related]
2. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC
Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391
[TBL] [Abstract][Full Text] [Related]
3. MORC2 regulates DNA damage response through a PARP1-dependent pathway.
Zhang L; Li DQ
Nucleic Acids Res; 2019 Sep; 47(16):8502-8520. PubMed ID: 31616951
[TBL] [Abstract][Full Text] [Related]
4. PARP1-modulated chromatin remodeling is a new target for cancer treatment.
Sinha S; Molla S; Kundu CN
Med Oncol; 2021 Aug; 38(10):118. PubMed ID: 34432161
[TBL] [Abstract][Full Text] [Related]
5. The PARP Way to Epigenetic Changes.
Ummarino S; Hausman C; Di Ruscio A
Genes (Basel); 2021 Mar; 12(3):. PubMed ID: 33804735
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
Rajawat J; Shukla N; Mishra DP
Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338
[TBL] [Abstract][Full Text] [Related]
7. The Enigmatic Function of PARP1: From PARylation Activity to PAR Readers.
Kamaletdinova T; Fanaei-Kahrani Z; Wang ZQ
Cells; 2019 Dec; 8(12):. PubMed ID: 31842403
[TBL] [Abstract][Full Text] [Related]
8. PARP inhibitor resistance: the underlying mechanisms and clinical implications.
Li H; Liu ZY; Wu N; Chen YC; Cheng Q; Wang J
Mol Cancer; 2020 Jun; 19(1):107. PubMed ID: 32563252
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.
Pettitt SJ; Krastev DB; Brandsma I; Dréan A; Song F; Aleksandrov R; Harrell MI; Menon M; Brough R; Campbell J; Frankum J; Ranes M; Pemberton HN; Rafiq R; Fenwick K; Swain A; Guettler S; Lee JM; Swisher EM; Stoynov S; Yusa K; Ashworth A; Lord CJ
Nat Commun; 2018 May; 9(1):1849. PubMed ID: 29748565
[TBL] [Abstract][Full Text] [Related]
10. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
Yazinski SA; Comaills V; Buisson R; Genois MM; Nguyen HD; Ho CK; Todorova Kwan T; Morris R; Lauffer S; Nussenzweig A; Ramaswamy S; Benes CH; Haber DA; Maheswaran S; Birrer MJ; Zou L
Genes Dev; 2017 Feb; 31(3):318-332. PubMed ID: 28242626
[TBL] [Abstract][Full Text] [Related]
11. The development of PARP as a successful target for cancer therapy.
Ferrara R; Simionato F; Ciccarese C; Grego E; Cingarlini S; Iacovelli R; Bria E; Tortora G; Melisi D
Expert Rev Anticancer Ther; 2018 Feb; 18(2):161-175. PubMed ID: 29260919
[TBL] [Abstract][Full Text] [Related]
12. The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.
Gatti M; Imhof R; Huang Q; Baudis M; Altmeyer M
Cell Rep; 2020 Aug; 32(5):107985. PubMed ID: 32755579
[TBL] [Abstract][Full Text] [Related]
13. Increased PARP1-DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1-DNA trapping is correlated with PARP1 inhibitor's cytotoxicity.
Chen HD; Chen CH; Wang YT; Guo N; Tian YN; Huan XJ; Song SS; He JX; Miao ZH
Int J Cancer; 2019 Aug; 145(3):714-727. PubMed ID: 30675909
[TBL] [Abstract][Full Text] [Related]
14. A Poly-ADP-Ribose Trigger Releases the Auto-Inhibition of a Chromatin Remodeling Oncogene.
Singh HR; Nardozza AP; Möller IR; Knobloch G; Kistemaker HAV; Hassler M; Harrer N; Blessing C; Eustermann S; Kotthoff C; Huet S; Mueller-Planitz F; Filippov DV; Timinszky G; Rand KD; Ladurner AG
Mol Cell; 2017 Dec; 68(5):860-871.e7. PubMed ID: 29220653
[TBL] [Abstract][Full Text] [Related]
15. PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistance.
Kanev PB; Atemin A; Stoynov S; Aleksandrov R
Semin Oncol; 2024; 51(1-2):2-18. PubMed ID: 37714792
[TBL] [Abstract][Full Text] [Related]
16. Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.
Gogola E; Duarte AA; de Ruiter JR; Wiegant WW; Schmid JA; de Bruijn R; James DI; Guerrero Llobet S; Vis DJ; Annunziato S; van den Broek B; Barazas M; Kersbergen A; van de Ven M; Tarsounas M; Ogilvie DJ; van Vugt M; Wessels LFA; Bartkova J; Gromova I; Andújar-Sánchez M; Bartek J; Lopes M; van Attikum H; Borst P; Jonkers J; Rottenberg S
Cancer Cell; 2018 Jun; 33(6):1078-1093.e12. PubMed ID: 29894693
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
18. Serine-linked PARP1 auto-modification controls PARP inhibitor response.
Prokhorova E; Zobel F; Smith R; Zentout S; Gibbs-Seymour I; Schützenhofer K; Peters A; Groslambert J; Zorzini V; Agnew T; Brognard J; Nielsen ML; Ahel D; Huet S; Suskiewicz MJ; Ahel I
Nat Commun; 2021 Jul; 12(1):4055. PubMed ID: 34210965
[TBL] [Abstract][Full Text] [Related]
19. HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs.
Valdez BC; Nieto Y; Yuan B; Murray D; Andersson BS
Oncotarget; 2022 Oct; 13():1122-1135. PubMed ID: 36243940
[TBL] [Abstract][Full Text] [Related]
20. A unified mechanism for PARP inhibitor-induced PARP1 chromatin retention at DNA damage sites in living cells.
Kanev PB; Varhoshkova S; Georgieva I; Lukarska M; Kirova D; Danovski G; Stoynov S; Aleksandrov R
Cell Rep; 2024 May; 43(5):114234. PubMed ID: 38758646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]